We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: revumenib
MedXY News
EnglishTag

revumenib

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib
Hematology-OncologyAMLBệnh Bạch Cầu Tế Bào Phôi

Immunophenotypic Evolution and Clinical Outcomes in R/R AML Treated with Revumenib

By MedXY|Mar 29, 2026

A study of 48 patients with R/R AML treated with revumenib revealed that 52% experienced dynamic immunophenotypic changes. Achieving MRD-negative morphologic remission significantly improved overall survival, highlighting the necessity for

Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival
Hematology-Oncologyacute myeloid leukemiaFlow Cytometry

Beyond Blast Counts: How Menin Inhibition Redefines AML Immunophenotypes and Survival

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Mar 16, 2026

This study explores how the menin inhibitor revumenib induces significant immunophenotypic shifts in AML patients. Results show that over 50% of patients undergo lineage changes, and achieving MRD negativity remains the strongest predictor

Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML
Hematology-Oncologymenin inhibitorNPM1-mutated AML

Revumenib: A New Menin Inhibitor Offering Hope for NPM1-Mutated Relapsed/Refractory AML

By MedXY|Oct 5, 2025

The phase 2 AUGMENT-101 study demonstrates that revumenib, a selective menin inhibitor, induces meaningful remissions and enables stem cell transplantation in heavily pretreated, older patients with relapsed or refractory NPM1-mutated AML,

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
Clinical UpdatesAMLazacitidine

Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

By MedXY|Oct 1, 2025

A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities